Last updated: August 5, 2026
Klor-Con is a potassium chloride replacement product whose commercial value depends on formulation performance, tolerability, supply reliability, and brand recognition rather than active-ingredient exclusivity. The U.S. product family includes extended-release potassium chloride tablets in 8, 10, 15, and 20 mEq strengths, with Klor-Con M20 representing the principal high-dose modified-release presentation. The active ingredient is generic and widely available, while formulation differentiation remains possible through release control, tablet size, administration flexibility, packaging, and patient-specific dosage forms. [1][2]
What is Klor-Con and how is it formulated?
Klor-Con is an oral potassium chloride replacement therapy used to treat or prevent hypokalemia when dietary or intravenous replacement is inappropriate. Potassium chloride is a high-dose electrolyte active that creates formulation, manufacturing, and tolerability constraints.
Klor-Con M extended-release tablets use a solid oral modified-release design. The product labeling identifies excipients that include microcrystalline cellulose, ethylcellulose, hypromellose, magnesium stearate, and talc. The exact excipient composition varies by strength and product presentation and should be controlled against the current FDA-approved label. [1][2]
Core excipient functions
| Excipient or material |
Likely formulation role |
Commercial relevance |
| Microcrystalline cellulose |
Diluent, compression aid, structural matrix |
Supports tablet hardness and manufacturability |
| Ethylcellulose |
Water-insoluble release-control polymer |
Helps moderate potassium chloride release |
| Hypromellose |
Film former, binder, viscosity and release-control polymer |
Supports coating integrity and dissolution control |
| Magnesium stearate |
Lubricant |
Controls ejection and manufacturing friction |
| Talc |
Anti-adherent and processing aid |
Supports tablet processing and coating performance |
The commercial objective is to release potassium gradually while limiting localized exposure of concentrated potassium chloride to the gastrointestinal mucosa. The label warns against crushing, chewing, or sucking extended-release tablets because altered release can increase adverse-event risk. [1]
What excipient strategy does Klor-Con use?
Klor-Con’s excipient strategy is based on a modified-release matrix or coated-tablet approach that permits high potassium loading in a swallowable oral dosage form. The formulation must balance five parameters:
- Potassium content per unit.
- Dissolution rate across gastrointestinal pH conditions.
- Tablet size and swallowability.
- Mechanical strength during packaging and distribution.
- Gastrointestinal tolerability.
Potassium chloride has a high active-mass requirement. A 20 mEq dose contains approximately 1.49 grams of potassium chloride, excluding excipients. That loading constrains the ability to use large quantities of specialty polymers, taste-masking systems, or functional coatings.
Why potassium chloride is difficult to formulate
Potassium chloride is highly soluble, saline, and potentially irritating to gastrointestinal tissue. Its high dose limits conventional approaches used for low-dose drugs, including extensive taste masking, multiparticulate encapsulation, and large quantities of lipid or polymer excipients.
The most important performance risks are:
- Tablet fracture that changes surface area and dissolution.
- Coating defects that create rapid potassium release.
- Moisture uptake during storage.
- Content nonuniformity in low-strength units.
- Excessive tablet size at higher strengths.
- Poor patient adherence caused by dysphagia or gastrointestinal discomfort.
FDA labeling for extended-release potassium chloride products emphasizes administration with meals and water and prohibits crushing or chewing. [1][2]
What formulations are protected by Klor-Con’s excipient design?
The principal protectable features are formulation and process attributes rather than potassium chloride itself. Potentially protectable subject matter includes:
- Specific polymer combinations and ratios.
- Coating thickness and weight gain.
- Layered or matrix tablet architecture.
- Dissolution profiles across multiple pH conditions.
- Tablet dimensions and compression parameters.
- Moisture-barrier packaging.
- Multiparticulate or sprinkle formulations.
- Liquid or powder products with taste-masking systems.
- Manufacturing controls that prevent dose dumping.
Klor-Con’s older U.S. product history does not create a strong assumption of current patent protection. Potassium chloride is an established active ingredient, and the core extended-release tablet concept has been commercially known for decades. Current Orange Book review is the controlling source for listed patents and regulatory exclusivity. [3]
What is the Orange Book status of Klor-Con?
Klor-Con’s commercial position is primarily regulatory and brand-based rather than dependent on a visible patent thicket. FDA Orange Book records distinguish approved applications, therapeutic equivalence, patent listings, and exclusivity. An approved product can continue to sell after patent expiry if it retains manufacturing capability, market recognition, and adequate supply economics. [3]
Patent and exclusivity assessment
| Issue |
Klor-Con assessment |
| Active-ingredient patent |
No meaningful composition-of-matter barrier for potassium chloride |
| New chemical entity exclusivity |
Not applicable to this established active |
| Pediatric exclusivity |
No product-specific protection assumed |
| Formulation patent risk |
Possible for newer release systems, but not intrinsic to potassium chloride |
| Method-of-use patent risk |
Low for standard potassium replacement indications |
| Orange Book significance |
Relevant for listed patents and approved application status |
| Brand protection |
Primarily trademark, product recognition, and manufacturing know-how |
No biosimilar pathway applies. Potassium chloride is a small-molecule electrolyte, so competitive entry occurs through abbreviated new drug applications, suitability pathways where applicable, or other conventional small-molecule approval routes rather than through biosimilar applications. [3][4]
When does Klor-Con lose exclusivity?
Klor-Con has no economically meaningful remaining active-ingredient exclusivity. Its practical exclusivity was established through product approval, manufacturing scale, brand awareness, and physician familiarity rather than a continuing monopoly over potassium chloride.
Generic potassium chloride extended-release products can compete when they obtain FDA approval and demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference product. The timing of generic entry depends on the reference-listed drug, ANDA approval, any listed patents, certification under Paragraph IV, and applicable settlement terms. [3][5]
Generic launch scenarios
| Scenario |
Commercial effect on Klor-Con |
| Multiple generic tablet suppliers |
Price compression and pharmacy substitution |
| One or two approved suppliers |
Moderate price competition; supply disruptions can support brand retention |
| Authorized generic or private-label supply |
Faster erosion of brand premium |
| Improved sprinkle or liquid entrant |
Segmentation away from conventional tablets |
| Manufacturing shortage |
Temporary pricing power for reliable suppliers |
| New abuse-resistant or tolerability-focused formulation |
Potential premium niche |
Which companies are challenging Klor-Con?
The relevant challengers are manufacturers of generic potassium chloride extended-release tablets, capsules, powders, and oral solutions. Competition is fragmented because potassium chloride is inexpensive, technically mature, and used across hospital, retail, long-term-care, and specialty-pharmacy channels.
The principal competitive dimensions are:
- FDA approval status.
- Therapeutic-equivalence rating.
- Dose strengths.
- Tablet size.
- Packaging configuration.
- Wholesale acquisition cost.
- Contract manufacturing reliability.
- Ability to supply institutional accounts.
- Availability during drug shortages.
The generic market does not need to duplicate every Klor-Con excipient. A competitor must meet the approved product’s quality, release, and bioequivalence requirements for its reference product. Small excipient changes can create meaningful regulatory and manufacturing consequences because release rate is central to product performance.
How strong is the Klor-Con patent estate?
Klor-Con’s patent estate appears commercially weak relative to products protected by active pharmaceutical ingredient, formulation, device, or biologic patents. Its defensible value lies in execution:
- Stable extended-release performance.
- Consistent tablet hardness and coating.
- Reliable dissolution after storage.
- Low complaint rates.
- National distribution.
- Pharmacist and prescriber familiarity.
- Established packaging and labeling.
A newer entrant could build patentable value around an excipient-enabled delivery system, but the claims would need to distinguish over known potassium chloride matrices and coated tablets. Broad claims covering potassium chloride plus common polymers would face prior-art risk. Stronger claims would focus on a narrow dissolution profile, a specific multilayer structure, a defined moisture-control system, or an administration method that solves a documented clinical problem.
What excipient opportunities exist for new Klor-Con competitors?
Smaller high-dose tablets
A dense tablet architecture could reduce tablet volume without sacrificing dissolution control. The opportunity is commercially attractive because high pill burden and swallowing difficulty are common barriers to potassium replacement. The technical challenge is maintaining tablet strength and consistent release at high active loading.
Sprinkle or dispersible products
A multiparticulate product that can be dispersed over soft food could address patients who cannot swallow tablets. The excipient system would need to maintain dose uniformity, prevent immediate release, limit grittiness, and avoid unacceptable taste. The product would also require clear instructions to prevent chewing the particles.
Taste-masked oral liquids
Liquid potassium chloride products have adherence advantages for some patients but face strong taste and gastrointestinal tolerability problems. Commercial opportunities include ion-exchange resins, polymeric taste barriers, flavor systems, and concentrated unit-dose packaging. The product must avoid excipient systems that alter potassium availability or create sedimentation and dosing errors.
Lower-irritation delivery systems
A formulation that reduces localized potassium concentration may support a tolerability claim, subject to clinical and regulatory substantiation. Multiparticulates, buffered vehicles, and controlled-release coatings are possible approaches. The strongest commercial value would come from improved persistence in patients who discontinue conventional tablets because of nausea, abdominal pain, or dyspepsia.
Moisture-resistant packaging
Packaging is an underused commercial differentiator for potassium chloride. High-barrier bottles, desiccant systems, unit-dose blister packs, and child-resistant unit-dose formats can reduce potency and dissolution variability caused by humidity. This opportunity is particularly relevant for mail-order, long-term-care, and high-temperature distribution channels.
What manufacturing and intellectual-property barriers exist?
The main barrier is process control, not raw-material access. Potassium chloride is inexpensive, but high-dose modified-release tablets require tight control of:
- Particle-size distribution.
- Polymer viscosity and substitution level.
- Granulation moisture.
- Compression force.
- Coating weight gain.
- Tablet friability.
- Dissolution profile.
- Packaging humidity.
- Cleaning validation for high-salt residues.
A competitor can often design around a brand’s excipient list, but it cannot design around the required quality attributes. A formulation that releases potassium too quickly may create safety concerns, while one that releases too slowly may fail therapeutic equivalence or clinical usability expectations.
What FDA regulatory status applies to Klor-Con?
Klor-Con is regulated as a prescription potassium chloride product. FDA labeling includes warnings concerning gastrointestinal lesions, dosing with meals and water, contraindications or precautions involving hyperkalemia, and interactions with potassium-sparing drugs and other agents that raise serum potassium. [1][2]
A new extended-release potassium chloride product would generally require:
- An ANDA referencing an appropriate listed drug, or another applicable FDA pathway.
- Demonstration of pharmaceutical equivalence.
- Bioequivalence or other FDA-accepted performance evidence.
- Comparative dissolution testing.
- Stability data.
- Container-closure qualification.
- Manufacturing controls for dose uniformity and release rate.
A product that materially changes the dosage form, release mechanism, or administration route may require a different regulatory strategy from a conventional generic tablet.
What patent litigation and Paragraph IV risks affect Klor-Con?
The Paragraph IV risk is tied to any patents listed for the specific reference product and application, not to potassium chloride generally. A challenger would assess:
- Whether the Orange Book lists formulation or method patents.
- Whether the listed patents remain enforceable.
- Whether the proposed product practices the claims.
- Whether a non-infringement or invalidity position is available.
- Whether launch-at-risk economics justify litigation exposure.
For an older potassium chloride product, litigation risk is more likely to involve formulation equivalence, manufacturing patents, or commercial-contract disputes than a basic active-ingredient patent. No broad biosimilar or biologic litigation framework applies.
How does Klor-Con compare with competing potassium chloride products?
| Attribute |
Klor-Con M extended-release tablet |
Generic ER tablet |
Oral solution or powder |
| Primary user |
Adults needing routine replacement |
Same population |
Patients with swallowing or dosing needs |
| Excipient priority |
Release control and tablet integrity |
Equivalence and cost |
Taste masking and suspension stability |
| Main commercial strength |
Brand familiarity and availability |
Low price |
Administration flexibility |
| Main risk |
GI intolerance and swallowing burden |
Substitution and price erosion |
Bad taste and dosing errors |
| IP opportunity |
Narrow formulation and process claims |
Limited unless differentiated |
Taste, packaging, and delivery claims |
| Distribution |
Retail, hospital, long-term care |
Broad generic channels |
Retail and institutional channels |
What licensing deals and commercial partnerships matter?
Klor-Con’s commercial value is more likely to arise from supply, distribution, contract manufacturing, and private-label arrangements than from major licensing transactions. Potassium chloride products are suitable for:
- Retail pharmacy supply agreements.
- Hospital group purchasing contracts.
- Long-term-care distribution.
- Authorized-generic arrangements.
- Contract manufacturing for regional labels.
- Co-branded adherence or specialty-pharmacy products.
A formulation owner with a differentiated sprinkle, liquid, or moisture-protected product could license the technology to an established generic manufacturer. The licensor’s leverage would depend on FDA approval status, demonstrated bioequivalence, manufacturing yield, and evidence of improved adherence or tolerability.
What revenue exposure does Klor-Con have?
Standalone Klor-Con revenue is not generally reported separately by public companies. The commercial exposure is concentrated in a mature, price-sensitive prescription category. Revenue depends on:
- Brand-to-generic substitution.
- Number of approved generic suppliers.
- Contract wins.
- Wholesale and pharmacy inventory.
- Product shortages.
- Dosage-strength mix.
- Retail versus institutional demand.
- Ability to retain patients who need a specific presentation.
The highest-value opportunity is not a broad premium on standard potassium chloride. It is a differentiated product that addresses a defined problem, such as swallowing difficulty, taste intolerance, adherence failure, or supply reliability.
Key Takeaways
- Klor-Con’s active ingredient has no meaningful modern composition-of-matter exclusivity.
- The formulation strategy relies on high-dose modified-release potassium chloride tablets.
- Excipients control release, tablet strength, processability, and gastrointestinal exposure.
- Patent strength is likely limited compared with newer drug products.
- Generic competition is the principal source of price pressure.
- The strongest commercial opportunities are smaller tablets, sprinkle products, taste-masked liquids, unit-dose packaging, and moisture-resistant systems.
- Manufacturing consistency and dissolution control are more important barriers than potassium chloride sourcing.
- No biosimilar pathway applies.
- Licensing opportunities are more likely in formulation technology and supply partnerships than in broad molecule rights.
FAQs About Klor-Con Excipient Strategy and Commercial Opportunities
Can a competitor use the same excipients as Klor-Con?
Yes. Excipients are not proprietary merely because they appear on a product label. A competitor must independently satisfy FDA quality, release, bioequivalence, and labeling requirements.
Is Klor-Con M20 protected by a formulation patent?
The existence and enforceability of any listed patent must be checked in the current FDA Orange Book for the relevant application. The commercial product’s age and the generic nature of potassium chloride indicate limited modern exclusivity compared with patented new-release systems.
Which excipient is most important in Klor-Con extended release?
Ethylcellulose and hypromellose are central release-control materials in the labeled formulation, while microcrystalline cellulose supports tablet structure. Performance depends on the complete formulation and process, not one excipient alone.
Can potassium chloride be reformulated as a pediatric sprinkle product?
Yes, but the product would need controlled particle size, dose uniformity, taste masking, release control, and administration instructions that prevent chewing or dose dumping. Pediatric development would also require age-appropriate safety and dosing evidence.
What is the best commercial whitespace around Klor-Con?
The strongest whitespace is an easier-to-administer potassium replacement product with documented advantages in swallowing, taste, gastrointestinal tolerability, packaging stability, or adherence. A conventional extended-release tablet with only a different excipient supplier would have limited pricing power.
References
- DailyMed. (n.d.). Klor-Con M20 potassium chloride extended-release tablets: Prescribing information. U.S. National Library of Medicine.
- DailyMed. (n.d.). Klor-Con potassium chloride extended-release tablets: Prescribing information. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2017). Guidance for industry: ANDAs for certain highly soluble, highly permeable, and highly absorbable drug products.
